ATHNdataset Registry

NCT ID: NCT06820515

Last Updated: 2025-04-01

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ENROLLING_BY_INVITATION

Total Enrollment

200000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2024-10-25

Study Completion Date

2055-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The Hemophilia Treatment Center (HTC) where you receive care is working with The American Thrombosis and Hemostasis Network (ATHN) to look at the quality of life of people with blood disorders and problems.

Doctors, scientists, policymakers, and other health care providers need a large amount of information from a lot of people to answer scientific, public health, and policy questions about better ways to treat blood disorders. They will use the information from the ATHNdataset to answer these questions.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Participants who agree to participate will let their health information be included in the ATHNdataset Registry, and the information will be updated regularly to reflect the participant's current health status. This registry includes collecting, storing and managing health information through a secure database. The following health information will be collected:

* Demographics (e.g., age, gender, income, education/occupation)
* The type of blood disorder you have
* Date you were diagnosed, or symptoms began
* Family history of the disorder
* Testing and assessments
* Physical exams
* Height, weight
* Vital signs, including blood pressure and heart rate
* Laboratory tests (results from blood or urine testing, or biological specimens)
* Genetic test results
* Imaging results (X-rays, CT scans, etc.)
* Pharmacokinetic testing results (how drugs are processed in the body)
* Medications used and any problems with use
* Types of bleeds, pain and clotting problems
* Treatments that stop your bleeding or clotting problems from occurring or getting worse
* Surgeries and/or procedures
* Immunizations (vaccines)
* Devices
* Routine care visits and injuries (trauma)
* Other illnesses and diseases you may have
* Allergies
* Patient-reported outcomes (PROs), questionnaires, and surveys
* Payment details for treatment, including insurance companies and health plans

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hemophilia Thrombosis Hemophilia A Hemophilia B Sickle Cell Disease Glanzmann Thrombasthenia Bleeding Disorder Blood Disorder Von Willebrand Diseases

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Blood Disorders

The ATHNdataset is a large, robust real-world registry that can be queried to produce curated subsets of data to support clinical care, outcomes analysis, safety monitoring, practice of treatment, advocacy, public health reporting, quality improvement projects, and research initiatives. Initiatives relying on the ATHNdataset may focus on gaining a greater understanding of blood disorders, the complications of these disorders, their social and economic costs, and the effectiveness of treatments.

The population includes all individuals diagnosed with or suspected to have a blood disorder. Participants will contribute data gathered during care encounters with an ATHN Affiliate.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Any participant evaluated for or the potential to have a blood disorder who has an encounter with an ATHN Affiliate.
* Participants of any age.
* Participant is able to provide consent or assent; a Legally Authorized Representative (LAR) may provide consent on a participant's behalf if a participant is unable to provide self-consent

Exclusion Criteria

* Any participant unable to provide consent or assent to participate in the ATHNdataset
Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

American Thrombosis and Hemostasis Network

NETWORK

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Tammuella Chrisentery-Singleton, M.D.

Role: PRINCIPAL_INVESTIGATOR

American Thrombosis and Hemostasis Network

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

American Thrombosis and Hemostasis Network

Hickory, North Carolina, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Pro00082318

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

ATHN 2: Factor Switching Study
NCT02546622 COMPLETED
Swiss Hemophilia Registry
NCT02512250 RECRUITING
Emicizumab in Patients With Acquired Hemophilia A
NCT05345197 ACTIVE_NOT_RECRUITING PHASE2